var data={"title":"Lamivudine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lamivudine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6432?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">see &quot;Lamivudine: Drug information&quot;</a> and <a href=\"topic.htm?path=lamivudine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lamivudine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709005\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lactic acidosis and severe hepatomegaly with steatosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs and other antiretrovirals. Discontinue lamivudine if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Exacerbations of hepatitis B:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy (including lamivudine-HBV) or are coinfected with hepatitis B virus (HBV) and HIV and have discontinued lamivudine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy or who discontinue lamivudine and are coinfected with HIV-1 and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Important differences among lamivudine-containing products:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lamivudine tablets and oral solution (used to treat HIV-1 infection) contain a higher dose of lamivudine than lamivudine-HBV tablets and oral solution (used to treat chronic hepatitis B infection). Patients with HIV-1 infection should receive only dosage forms appropriate for treatment of HIV-1.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of HIV-1 resistance if lamivudine-HBV is used in patients with unrecognized or untreated HIV-1:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lamivudine-HBV is not approved for the treatment of HIV-1 infection because the lamivudine dosage in lamivudine-HBV is subtherapeutic and monotherapy is inappropriate for the treatment of HIV-1 infection. HIV-1 resistance may emerge in chronic hepatitis B-infected patients with unrecognized or untreated HIV-1 infection. HIV counseling and testing should be offered to all patients before beginning treatment with lamivudine-HBV and periodically during treatment.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186636\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Epivir;</li>\n      <li>Epivir HBV</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186637\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>3TC;</li>\n      <li>Heptovir</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053582\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">HIV Agents (Anti-HIV Agents)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nucleoside Reverse Transcriptase Inhibitor (NRTI)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443760\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 infection, treatment:</b> Use in combination with other antiretroviral agents: Oral: Epivir: 2 mg/kg/dose twice daily (HHS [pediatric] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 perinatal transmission, prevention </b>(HHS [perinatal] 2017): <b>Note:</b> A combination prophylaxis regimen is recommended for neonates at a higher risk of HIV acquisition, including neonates born to HIV-infected mothers who have not received antepartum or intrapartum antiretroviral (ARV) therapy, have received only intrapartum ARV therapy, or received antepartum ARV therapy but with suboptimal viral suppression. Prevention therapy should begin as soon as possible after birth (within 6 to 12 hours after delivery). If neonate is diagnosed as HIV positive, discontinue prevention (prophylaxis) dosing and begin a treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Three-drug combination (with nevirapine and zidovudine): Limited data available: GA &ge;32 weeks: Oral: Epivir: 2 mg/kg/dose twice daily; at 4 weeks of age, increase dose to 4 mg/kg/dose twice daily; total duration: 2 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 nonoccupational postexposure prophylaxis</b> (nPEP) (HHS [nPEP] 2016): <b>Note:</b> Initiate therapy within 72 hours of exposure and continue for 28 days in combination with other antiretrovirals: Oral: Epivir: 2 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment for HIV</b>: Insufficient data exist to recommend specific dosing adjustments for renal impairment; consider reducing the dose or increasing the dosing interval; use with caution; monitor closely; drug is renally eliminated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053575\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">see &quot;Lamivudine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 perinatal transmission, prevention </b>(HHS [perinatal] 2017): <b>Note:</b> A combination prophylaxis regimen is recommended for neonates at a higher risk of HIV acquisition, including neonates born to HIV-infected mothers who have not received antepartum or intrapartum antiretroviral (ARV) therapy, have received only intrapartum ARV therapy, or received antepartum ARV therapy but with suboptimal viral suppression. Prevention therapy should begin as soon as possible after birth (within 6 to 12 hours after delivery). If neonate is diagnosed as HIV positive, discontinue prevention (prophylaxis) dosing and begin a treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Three-drug combination (with nevirapine and zidovudine): Limited data available: Infants &le;6 weeks (GA &ge;32 weeks): Oral: Epivir: 4 mg/kg/dose every 12 hours; total duration: 2 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 infection, treatment:</b> Use in combination with other antiretroviral agents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants 1 month to &lt;3 months: Epivir: Oral solution (10 mg/mL): 4 mg/kg/dose twice daily (HHS [pediatric] 2017; Tremoulet 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants &ge;3 months, Children, and Adolescents: <b>Note</b>: Scored tablet is preferred formulation in patients weighing &ge;14 kg who are able to take a solid oral dosage form; use of oral solution has been associated with lower rates of virologic suppression, lower plasma exposure, and increase rates of resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Twice daily dosing: Epivir:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral solution (10 mg/mL): 4 mg/kg/dose twice daily; maximum dose: 150 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral tablet: Weight-band dosing for patients weighing &ge;14 kg who are able to swallow tablets (using scored 150 mg tablets):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">14 to &lt;20 kg: 75 mg (<sup>1</sup>/<sub>2</sub> tablet) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">20 to &lt;25 kg: 75 mg (<sup>1</sup>/<sub>2</sub> tablet) in the morning and 150 mg (1 tablet) in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;25 kg: 150 mg (1 tablet) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Once-daily dosing: Epivir: <b>Note:</b> Not recommended as initial therapy, especially with use of the oral solution in infants and young children. Efficacy of once-daily dosing has only been demonstrated in patients who transitioned from twice-daily dosing after 36 weeks of treatment. Some experts recommend reserving once-daily therapy for use as a component of a once-daily regimen in clinically stable patients &ge;3 years of age who have undetectable viral loads and stable CD4 counts (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral solution (10 mg/mL):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Manufacturer's labeling:</i> 8 mg/kg/dose once daily; maximum dose: 300 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Alternate dosing (HHS [pediatric] 2017):</i> 8 to 10 mg/kg/dose once daily; maximum dose: 300 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral tablet: Weight-band dosing for patients &ge;14 kg who are able to swallow tablets (scored 150 mg tablets):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">14 to &lt;20 kg: 150 mg (1 tablet) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">20 to &lt;25 kg: 225 mg (1 + <sup>1</sup>/<sub>2</sub> tablet) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;25 kg: 300 mg (2 tablets) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 nonoccupational postexposure prophylaxis (nPEP)</b> (HHS [nPEP] 2016): <b>Note:</b> Initiate therapy within 72 hours of exposure and continue for 28 days in combination with other retroviral agents; Oral: Epivir:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents &lt;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: Oral solution (10 mg/mL): 4 mg/kg twice daily; maximum dose: 150 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-band dosing: Oral tablet: For patients &ge;14 kg who are able to swallow tablets (scored 150 mg tablets):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">14 to &lt;20 kg: 75 mg (<sup>1</sup>/<sub>2</sub> tablet) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">20 to &lt;25 kg: 75 mg (<sup>1</sup>/<sub>2</sub> tablet) in the morning and 150 mg (1 tablet) in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;25 kg: 150 mg (1 tablet) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;16 years: Oral solution (10 mg/mL) or oral tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;50 kg: 4 mg/kg twice daily; maximum dose: 150 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;50 kg: 150 mg twice daily or 300 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatitis B, treatment (Epivir-HBV) (non-HIV-exposed/-positive):</b> <b>Note:</b> Use in HBV treatment is discouraged due to rapid resistance development; consider use only if other anti-HBV antiviral regimens with more favorable resistance patterns cannot be used. Children &ge;2 years and Adolescents: Oral: 3 mg/kg/dose once daily; maximum daily dose: 100 mg/<b>day </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AASLD practice guidelines (Lok 2009): Treatment duration:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat &ge;1 year until HBeAg confirmed seroconversion and undetectable serum HBV DNA; continue therapy for &ge;6 months after HBeAg seroconversion</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HBeAg negative chronic hepatitis: Treat &gt;1 year until hepatitis B surface antigen (HBsAg) clearance</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Patients not achieving &lt;2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy (Lok 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatitis B/HIV coinfection, treatment of both infections:</b> Epivir: Infants, Children, and Adolescents: Oral: 4 mg/kg/dose twice daily; maximum dose: 150 mg/dose; in combination with other antiretrovirals in a HAART regimen; <b>Note:</b> The formulation and dosage of Epivir-HBV are not appropriate to treat patients infected with both HBV and HIV (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 infection, treatment:</b> Use with at least two other antiretroviral agents: Oral: 150 mg twice daily or 300 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatitis B, treatment (Epivir-HBV) (non-HIV-exposed/-positive): Note:</b> Use in HBV treatment is discouraged due to rapid resistance development; consider use only if other anti-HBV antiviral regimens with more favorable resistance patterns cannot be used. Oral: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatitis B/HIV-1 coinfection, treatment of both infections:</b> Epivir: Oral: 150 mg twice daily or 300 mg once daily, in combination with other antiretrovirals in a HAART regimen. <b>Note:</b> The formulation and dosage of Epivir-HBV are not appropriate for patients infected with both HBV and HIV.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment for HIV-1 infection: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &lt;25 kg: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; consider reducing the dose or increasing the dosing interval; use with caution; monitor closely</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &ge;25 kg and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;50 mL/minute: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 49 mL/minute: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 15 to 29 mL/minute: 150 mg first dose, then 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 5 to 14 mL/minute: 150 mg first dose, then 50 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;5 mL/minute: 50 mg first dose, then 25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Negligible amounts are removed by 4-hour hemodialysis or peritoneal dialysis. On dialysis days, take dose after dialysis; additional dose of lamivudine is not required (HHS [adult] 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: The following dosage adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 4 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 2 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 1 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis (IHD): 1 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): 1 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): 4 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment for chronic hepatitis B (Epivir-HBV): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; data is insufficient; reduction in the dose should be considered; use with caution; monitor closely</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;50 mL/minute: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 49 mL/minute: 100 mg first dose, then 50 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 15 to 29 mL/minute: 100 mg first dose, then 25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 5 to 14 mL/minute: 35 mg first dose, then 15 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;5 mL/minute: 35 mg first dose, then 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Negligible amounts are removed by 4-hour hemodialysis or peritoneal dialysis. Additional dose of lamivudine after routine (4 hour) peritoneal or hemodialysis is not required</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No dosage adjustments required; use with caution in patients with decompensated liver disease; safety and efficacy not established with these patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186610\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epivir: 10 mg/mL (240 mL) [contains methylparaben, propylene glycol, propylparaben; strawberry-banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epivir HBV: 5 mg/mL (240 mL) [contains methylparaben, propylene glycol, propylparaben; strawberry-banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (240 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epivir: 150 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epivir: 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epivir HBV: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 150 mg, 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186595\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053586\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered without regard to meals</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186631\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epivir: Store at 25&deg;C (77&deg;F) tightly closed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epivir HBV: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) tightly closed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053585\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epivir: Treatment of HIV-1 infection in combination with other antiretroviral agents (FDA approved in ages &ge;3 months and adults); <b>Note:</b> HIV regimens consisting of three antiretroviral agents are strongly recommended; has also been used for nonoccupational HIV postexposure prophylaxis (nPEP) and prevention of maternal-fetal transmission of HIV infection. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epivir-HBV: Management of chronic hepatitis B infection associated with evidence of hepatitis B viral replication and active liver inflammation (FDA approved in ages &ge;2 years and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186683\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LamiVUDine may be confused with lamoTRIgine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epivir may be confused with Combivir</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186681\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, depression, dizziness, fatigue, headache, insomnia, neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, abdominal cramps, anorexia, diarrhea, dyspepsia, heartburn, increased amylase, increased serum lipase, nausea, pancreatitis (more common in pediatric patients), sore throat, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemoglobinemia, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection (includes ear, nose, and throat)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, increased creatine phosphokinase, musculoskeletal pain, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, nasal signs and symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Alopecia, anaphylaxis, anemia, exacerbation of hepatitis B, hepatomegaly, hyperbilirubinemia, hyperglycemia, immune reconstitution syndrome, lactic acidosis, liver steatosis, lymphadenopathy, myasthenia, paresthesia, peripheral neuropathy, pruritus, pure red cell aplasia, redistribution of body fat, rhabdomyolysis, splenomegaly, stomatitis, urticaria, weakness, wheezing </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186616\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to lamivudine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186599\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fat redistribution: May cause redistribution/accumulation of fat (eg, central obesity, buffalo hump, peripheral wasting, facial wasting, breast enlargement, cushingoid appearance).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis/hepatomegaly: <b>[US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases; suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity;</b> use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy, or prolonged exposure); transaminase elevation may/may not accompany hepatomegaly and steatosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Has been reported, particularly in HIV-infected children with a history of nucleoside use. Discontinue treatment if signs of symptoms of pancreatitis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic hepatitis B: <b>[US Boxed Warning]: </b><b>Severe acute exacerbations of hepatitis B (some fatal) have been reported in patients with HBV or HIB/HBV coinfection who have discontinued lamivudine; hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months after discontinuation. <b>Initiate antihepatitis B (HBV) medications if clinically appropriate.</b></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Resistance:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- HIV: <b>[US Boxed Warning]: HIV-1 resistance may emerge in chronic hepatitis B-infection patients with unrecognized or untreated HIV-1 infection. Counseling and HIV testing should be offered to all patients before beginning treatment with lamivudine for hepatitis B and then periodically during treatment. Lamivudine dosing for hepatitis B is subtherapeutic if used for HIV-1 infection treatment. Lamivudine monotherapy is not appropriate for HIV-1 infection treatment.</b> Lamivudine resistant HIV-1 can develop rapidly and limit treatment options if used in unrecognized or untreated HIV-1 infection or if a patient becomes coinfected during HBV treatment. Lamivudine dosing for hepatitis B is also subtherapeutic if used for HIV-1/HBV coinfection treatment. If lamivudine is chosen as part of a HIV-1 treatment regimen in coinfected patients, the higher lamivudine dosage indicated for HIV-1 therapy should be used, with other drugs, in an appropriate combination regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- HBV: Patients treated with lamivudine-HBV with YMDD-mutant HBV showed diminished treatment response (lower rates of HbeAg seroconversion and HbeAg loss, more frequent return of positive HBV DNA, more frequent ALT elevations) compared to patients without evidence of YMDD substitutions. Emergence of lamivudine resistant HBV variants has also been reported in HIV-1/HBV coinfected patients who have received lamivudine-containing antiretroviral regimens.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interferon alfa: Use with caution in combination with interferon alfa with or without ribavirin in HIV/HCV coinfected patients; monitor closely for hepatic decompensation, anemia, or neutropenia; dose reduction or discontinuation of interferon and/or ribavirin may be required if toxicity evident.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in pediatric patients with a history of prior antiretroviral nucleoside exposure or pancreatitis, or other significant risk factors for development of pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate product selection: Epivir HBV: <b>[US Boxed Warning]: Do not use Epivir HBV tablets or Epivir HBV oral solution for the treatment of HIV. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral solution: Use of lamivudine oral solution has been associated with lower rates of virologic suppression, lower plasma lamivudine exposure, and increased rates of resistance when compared to lamivudine tablets in pediatric clinical trials. Lamivudine scored tablet is the preferred formulation for HIV-1 infected pediatric patients weighing &ge;14 kg and for whom a solid dosage form is appropriate; consider more frequent monitoring of HIV-1 viral load if oral solution is used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sucrose: Lamivudine oral solutions contains 3 g of sucrose/15 mL; advise diabetic patients of sucrose content.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">-HIV: Do not use as monotherapy in treatment of HIV. Treatment of HIV in patients with unrecognized/untreated HBV may lead to rapid HBV resistance; HIV-infected patients should be screened for hepatitis B prior to starting lamivudine HIV therapy. Lamivudine combined with emtricitabine is not recommended as a dual-nucleoside reverse transcriptase inhibitor (NRTI) combination due to similar resistance patterns and negligible additive antiviral activity. Do not use lamivudine/abacavir (plus efavirenz or plus atazanavir/ritonavir) in adolescent and adult HIV-1 patients with a pre-ART HIV RNA &gt;100,000 copies/mL (HHS [adult] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- HBV: Current clinical hepatitis B practice guidelines do not recommend lamivudine for initial use in the management of chronic HBV due to low barrier to resistance; other antiviral agents with a high genetic barrier to drug resistance are preferred (eg, tenofovir or entecavir) (AASLD [Terrault 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- HIV/HBV coinfection: Lamivudine and tenofovir is a recommended NRTI backbone in a fully suppressive antiretroviral regimen to provide activity against both HIV and HBV (HHS [adult] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26021936\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The major clinical toxicity of lamivudine in pediatric patients is pancreatitis which has occurred in 14% of patients in one open-label, uncontrolled study; discontinue lamivudine therapy if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur. Use with extreme caution and only if there is no satisfactory alternative therapy in pediatric patients with a history of pancreatitis or other significant risk factors for the development of pancreatitis. Infants receiving lamivudine in combination with nelfinavir (powder no longer available in the US) and zidovudine for prevention of maternal-fetal transmission experienced a higher rate of neutropenia compared to zidovudine/nevirapine combination or zidovudine alone (27.5% vs 15%). Other studies in infants reported significantly higher rates of anemia and neutropenia when lamivudine was administered in combination with zidovudine (HHS [perinatal] 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299572\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> MRP2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186604\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12942&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Emtricitabine: LamiVUDine may enhance the adverse/toxic effect of Emtricitabine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sorbitol: May decrease the serum concentration of LamiVUDine. Management: When possible, avoid chronic coadministration of sorbitol-containing solutions with lamivudine, but if this combination cannot be avoided, monitor patients more closely for possible therapeutic failure associated with decreased lamivudine exposure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of LamiVUDine.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186632\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases the rate of absorption and C<sub>max</sub>; however, there is no change in the systemic AUC. Management: Administer with or without food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186620\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Lamivudine has a high level of transfer across the human placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may increase the risk of preterm delivery, although available information is conflicting possibly due to variability of maternal factors (disease severity; gestational age at initiation of therapy); however, maternal antiretroviral medication should not be withheld due to concerns of preterm birth. Based on data collected by the antiretroviral pregnancy registry, the risk of spontaneous abortions, induced abortions, and preterm birth is less in lamivudine-containing regimens compared with regimens without lamivudine. Information related to stillbirth, low birth weight, and small for gestational age infants is limited. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children who develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential mitochondrial dysfunction. Cases of lactic acidosis and hepatic steatosis related to mitochondrial toxicity have been reported with use of nucleoside reverse transcriptase inhibitors (NRTIs). These adverse events are similar to other rare but life-threatening syndromes that occur during pregnancy (eg, HELLP syndrome). In general, NRTIs are well tolerated and the benefits of use generally outweigh potential risk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Health and Human Services (HHS) Perinatal HIV Guidelines consider lamivudine in combination with either abacavir or tenofovir disoproxil fumarate to be a preferred NRTI backbone for initial therapy in antiretroviral-naive pregnant females. The lamivudine/abacavir backbone is not recommended with atazanavir/ritonavir or efavirenz if pretreatment HIV RNA is &gt;100,000 copies/mL. The guidelines consider lamivudine with zidovudine to be an alternative NRTI backbone for initial therapy in antiretroviral-naive pregnant females. The guidelines also consider lamivudine plus tenofovir disoproxil fumarate a recommended dual NRTI backbone in regimens for HIV/HBV-coinfected pregnant females. Use caution with hepatitis B coinfection; hepatitis B flare may occur if lamivudine is discontinued. The pharmacokinetics of lamivudine during pregnancy are not significantly altered, and dosage adjustment is not required.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, ART is recommended for all pregnant females with HIV to keep the viral load below the limit of detection and reduce the risk of perinatal transmission. When HIV is diagnosed during pregnancy in a female who has never received antiretroviral therapy, ART should begin as soon as possible after diagnosis. Females who become pregnant on a stable ART regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated. Monitoring during pregnancy is more frequent than in nonpregnant adults; ART should be continued postpartum for all females living with HIV.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In hepatitis B-infected women (not coinfected with HIV), the AASLD chronic hepatitis B treatment guidelines suggest antiviral therapy to reduce the risk of perinatal transmission of hepatitis B in HBsAg-positive pregnant women with an HBV DNA &gt;200,000 units/mL. There are limited data on the level of HBV DNA for when antiviral therapy is routinely recommended (&gt;200,000 units/mL is a conservative recommendation); however, the AASLD recommends against antiviral therapy to reduce the risk of perinatal transmission in HBsAg-positive pregnant women with an HBV DNA &le;200,000 units/mL. Lamivudine is one of the antivirals that has been studied in pregnant women, with most studies initiating antiviral therapy at 28 to 32 weeks gestation and discontinuing antiviral therapy between birth to 3 months postpartum (monitor for ALT flares every 3 months for 6 months following discontinuation). There is insufficient long-term safety data in infants born to mothers who took antiviral agents during pregnancy (AASLD [Terrault 2016]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll pregnant females exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or http://www.APRegistry.com). Health care providers caring for HIV-infected females and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053581\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatitis B: Screen for HIV before starting lamivudine; monitor LFTs prior to, periodically during, and for at least several months after discontinuation; monitor HBV DNA levels periodically during treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HIV: <b>Note:</b> The absolute CD4 cell count is currently recommended to monitor immune status in children of all ages; CD4 percentage can be used as an alternative in children &lt;5 years of age. This recommendation is based on the use of absolute CD4 cell counts in the current pediatric HIV infection stage classification and as thresholds for urgency of initiation of antiretroviral treatment (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Screen for hepatitis B before starting lamivudine (in patients who previously demonstrated no immunity to hepatitis B). Also prior to initiation of therapy: Genotypic resistance testing, CD4 and viral load (every 3 to 4 months), CBC with differential, LFTs, BUN, creatinine, electrolytes, glucose, urinalysis (every 6 to 12 months), and assessment of readiness for adherence with medication regimen. At initiation and with any change in treatment regimen: Hepatitis B screening (at change in therapy, in patients who previously demonstrated no immunity to hepatitis B), CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, urinalysis (at initiation), BUN, creatinine, albumin, total protein, lipid panel (at initiation), CD4, and viral load. After 1 to 2 weeks of therapy: Signs of medication toxicity and adherence. After 2 to 4 weeks of therapy: CBC with differential, viral load, signs of medication toxicity, and adherence; then every 3 to 4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, viral load, signs of medication toxicity, and adherence. Lipid panel and urinalysis every 6 to 12 months. CD4 monitoring frequency may be decreased to every 6 to 12 months in children who are adherent to therapy if the value is well above the threshold for opportunistic infections, viral suppression is sustained, and the clinical status is stable for more than 2 to 3 years. In patients with known or suspected complex drug resistance patterns, phenotypic resistance testing (usually in addition to genotypic resistance testing) should be performed (HHS [pediatric] 2017). Monitor for growth and development, signs of HIV-specific physical conditions, HIV disease progression opportunistic infections, pancreatitis, or lactic acidosis. Infants receiving lamivudine for prevention of maternal-fetal HIV transmission: Hemoglobin and neutrophil counts at 4 weeks after initiation of prophylaxis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186598\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Lamivudine is a cytosine analog. In vitro, lamivudine is triphosphorylated, the principle mode of action is inhibition of HIV reverse transcription via viral DNA chain termination; inhibits RNA- and DNA-dependent DNA polymerase activities of reverse transcriptase. In hepatitis B, the monophosphate form of lamivudine is incorporated into the viral DNA by hepatitis B virus polymerase, resulting in DNA chain termination.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186615\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Into extravascular spaces</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children (n=38): CSF concentrations were 14.2% &plusmn; 7.9% of the serum concentration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>: 1.3 &plusmn; 0.4 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Plasma: &lt;36%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minor; only known metabolite is trans-sulfoxide metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Absolute; Cp<sub>max</sub> decreased with food although AUC not significantly affected</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: Oral solution: 66% &plusmn; 26%; relative bioavailability is 40% lower than with tablets</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents and Adults: Oral solution: 87% &plusmn; 13%; Tablet 150 mg: 86% &plusmn; 16%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intracellular: 10 to 15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 4 months to 14 years: 2 &plusmn; 0.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 5 to 7 hours; increased with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients 0.5 to 17 years: Median: 1.5 hours (range: 0.5 to 4 hours) (Lewis 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents 13 to 17 years: 0.5 to 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Fed: 3.2 hours; Fasted: 0.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily urine (majority as unchanged drug); weight-corrected oral clearance is highest at age 2 years, then declines from age 2 to 12 years, where values then remain comparable to adult values</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186619\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Epivir HBV Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (240 mL): $234.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Epivir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (240 mL): $133.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LamiVUDine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (240 mL): $119.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Epivir HBV Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $1,170.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Epivir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $498.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $498.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LamiVUDine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $966.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $429.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $429.66</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186623\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>3TC (AE, AR, AU, BH, BM, BS, BZ, CR, DO, GT, GY, HK, HN, ID, JM, KR, KW, MX, NI, NZ, PA, QA, SR, SV, TT, UY, ZW);</li>\n      <li>3TC-HBV (ID);</li>\n      <li>Cytivir (BD);</li>\n      <li>Epivir (AE, AT, BB, BE, BH, BR, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HN, HR, HU, IE, IL, IQ, IR, IS, IT, JO, KW, LB, LT, LU, LV, LY, MT, NL, NO, OM, PE, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SY, TH, TR, UA, VE, VN, YE);</li>\n      <li>Epivir 3TC (CL);</li>\n      <li>Glamivir (VN);</li>\n      <li>Heplav (ID);</li>\n      <li>Heptavir (ET, LK, UA);</li>\n      <li>Heptodin (CN);</li>\n      <li>Inhavir (CO);</li>\n      <li>Koide (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Ladiwin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Lamid (BD);</li>\n      <li>Lamidac (IN);</li>\n      <li>Lamidin (BD);</li>\n      <li>Lamidine (TW);</li>\n      <li>Lamiffix (KR);</li>\n      <li>Lamivir (LB, PE, TH);</li>\n      <li>Tabivir (QA);</li>\n      <li>Tizacure (HK);</li>\n      <li>Vuclodir (PY);</li>\n      <li>Zeffiks (UA);</li>\n      <li>Zeffix (AE, AT, AU, BD, BE, BG, BH, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, HU, IE, IL, IT, JO, KR, KW, LB, LT, LU, LV, MT, MY, NL, NO, NZ, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, VN);</li>\n      <li>Zeraffic (HK, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007, 161.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Epivir (lamivudine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Epivir HBV (lamivudine) [prescribing information]. Research Triangle Park, NC; GlaxoSmithKline; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. December 2016. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. May 2015. Available at <a href=\"http://www.aidsinfo.nih.gov/\" target=\"_blank\">http://www.aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &quot;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&quot; April 2017. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. March 2017. Available at <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Updated March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis LL, Venzon D, Church J, et al, &ldquo;Lamivudine in Children With Human Immunodeficiency Virus Infection: A Phase I/II Study,&rdquo; <i>J Infect Dis</i>, 1996, 174(1):16-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-pediatric-drug-information/abstract-text/8655986 /pubmed\" target=\"_blank\" id=\"8655986 \">8655986 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lok AS and McMahon BJ, &quot;Chronic Hepatitis B: Update 2009,&quot; <i>Hepatology</i>, 2009, 50(3):661-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-pediatric-drug-information/abstract-text/19714720/pubmed\" target=\"_blank\" id=\"19714720\">19714720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nielsen-Saines K, Watts DH, Veloso VG, et al, &quot;Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection,&quot; <i>N Engl J Med</i>, 2012, 366(25):2368-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-pediatric-drug-information/abstract-text/22716975/pubmed\" target=\"_blank\" id=\"22716975\">22716975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Agency of Canada (PHAC), Canadian Guidelines on Sexually Transmitted Infection. Last modified December 2013. Available at http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php. Accessed December 30, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. <i>Hepatology</i>. 2016;63(1):261-283. doi: 10.1002/hep.28156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-pediatric-drug-information/abstract-text/26566064/pubmed\" target=\"_blank\" id=\"26566064\">26566064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tremoulet AH, Capparelli EV, Patel P, et al, &quot;Population Pharmacokinetics of Lamivudine in Human Immunodeficiency Virus-Exposed and -Infected Infants,&quot; <i>Antimicrob Agents Chemother</i>, 2007, 51(12):4297-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-pediatric-drug-information/abstract-text/17893155/pubmed\" target=\"_blank\" id=\"17893155\">17893155</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12942 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709005\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F186636\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F186637\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053582\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443760\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053575\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F186610\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F186595\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1053586\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F186631\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1053585\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F186683\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F186681\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F186616\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F186599\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26021936\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299572\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F186604\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F186632\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F186620\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053581\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F186598\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F186615\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F186619\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F186623\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12942|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">Lamivudine: Drug information</a></li><li><a href=\"topic.htm?path=lamivudine-patient-drug-information\" class=\"drug drug_patient\">Lamivudine: Patient drug information</a></li></ul></div></div>","javascript":null}